Are We Measuring Metabolic Health All Wrong?
A fragmented system built on isolated metrics like BMI and A1C fails to capture the full picture of metabolic health and limits our ability to manage it effectively.
Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial
Eli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study are scheduled for presentation next month during the American Diabetes Association Scientific Sessions meeting.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Report: How Employers Can Better Manage GLP-1s for Adolescents
A new Nomi Health report found that GLP-1 use and spending among adolescents rose sharply from 2022 to 2025, raising concerns about future costs for self-insured employers.
Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs
Kailera Therapeutics’ IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue.
Eli Lilly Gets Speedy FDA Nod for Oral GLP-1 Drug, a Competitor to New Novo Nordisk Pill
FDA approval for Eli Lilly’s oral GLP-1 drug, Foundayo, comes about three months after Novo Nordisk launched its Wegovy pill. While clinical trial results for both daily pills showed comparable weight reduction, Lilly’s pill offers patients a slight dosing advantage.
Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test
Structure Therapeutics’ aleniglipron, a once-daily oral GLP-1 drug, led to an average 16% weight loss measured at 44 weeks. Based on these results, the biotech is preparing for Phase 3 testing expected to begin in the second half of this year.
presented by
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Roche, Zealand Pharma Obesity Drug Meets Clinical Trial’s Weight Loss Goals, But Can It Compete?
Petrelintide posted Phase 2 results showing tolerability comparable to a placebo, but average weight loss that was less than what analysts expected. The Zealand Pharma drug, in development under a partnership with Roche, is a peptide engineered to activate the amylin receptor.
Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds
Vivtex’s technology uses AI and high throughput screening to identify the combinations of drug ingredients that can deliver peptides through gastrointestinal tissue. Besides Novo Nordisk, the MIT spinout’s partners include Astellas Pharma, Equillium, and Orbis Medicines.
Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity
A monthly injectable GLP-1 drug from Pfizer’s $10 billion Metsera acquisition is now on track for a Phase 3 program spanning 10 pivotal studies this year. While Pfizer’s pipeline spans internally developed and in-licensed assets for other targets, the pharma company says the Metsera drug is the foundation for its obesity strategy pursuing monotherapies and combination treatments.
AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
AstraZeneca’s deal with CSPC Pharmaceutical Group includes a Phase 1-ready obesity drug that hits the same targets as Eli Lilly’s obesity drug Zepbound, but with monthly dosing. The new collaboration builds on an existing drug R&D relationship between the two companies.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Roche Obesity Drug’s Phase 2 Results Are Competitive, But True Test May Come From Combo Studies
Preliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity.
Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss
Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.
Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China
YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations.
Could Trump do for Branded Expensive Drugs What He Just Did for GLP-1s?
The Trump administration’s new deal lowers prices and expands access to GLP-1 drugs, but experts argue far broader reforms are needed to address high prescription drug costs overall.
Kailera Secures $600M to Advance Dual-Targeting Obesity Drug to Global Phase 3 Tests
Bain Capital Private Equity led Kailera Therapeutics’ Series B financing, which will support global Phase 3 tests of KAI-9531, a weekly injectable drug that hits the same targets as Eli Lilly’s blockbuster obesity medication, Zepbound. The capital will also support development of other oral and injectable metabolic medicines in Kailera’s pipeline.